文献速递胸部肿瘤

早期切除非小细胞肺癌辅助化疗四项试验中TP53与KRAS或EGFR共突变状态预后及预测作用的汇总分析

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
PubMed 文献 · J Clin Oncol · 2017-04-28

该汇总分析纳入四项辅助化疗随机试验的3533例非小细胞肺癌患者,其中1181例(557例死亡)用于TP53/KRAS分析,404例(170例死亡)用于TP53/EGFR分析。TP53/KRAS共突变无预后效应(P=0.61),但化疗对其有边缘性预测效应(P=0.04),TP53/KRAS共突变者化疗较野生型/野生型有害(HR 2.49,95%CI 1.10-5.64,P=0.03)。腺癌中TP53/EGFR共突变既无预后(P=0.83)也无显著预测作用(P=0.86)。

要点

  • TP53/KRAS共突变无预后效应(P=0.61),对化疗有边缘性预测效应(P=0.04)。
  • TP53/KRAS共突变者辅助化疗较野生型/野生型有害(HR 2.49,95%CI 1.10-5.64,P=0.03)。
  • 腺癌中TP53/EGFR共突变无预后(P=0.83)及显著预测作用(P=0.86)。

核心结论

  • 未发现KRAS或EGFR驱动基因与TP53抑癌基因共突变的预后效应。
  • TP53/KRAS共突变对化疗的潜在负向预测效应需验证。

研究设计与样本

  • 汇总分析四项辅助化疗对比观察的随机试验,纳入3533例非小细胞肺癌患者。
  • TP53、KRAS、EGFR突变分析由多个实验室以盲法完成。
  • 主要终点为总生存,次要终点为无病生存。
  • 采用按试验分层的多变量Cox比例风险模型评估TP53/KRAS共突变(全部患者及腺癌亚组)和TP53/EGFR共突变(仅腺癌)。

主要发现

  • TP53/KRAS分析纳入1181例(557例死亡),TP53/EGFR分析纳入404例(170例死亡)。
  • TP53/KRAS突变状态无预后效应(P=0.61),有边缘性预测效应(P=0.04)。
  • TP53/KRAS共突变者化疗较野生型/野生型有害(HR 2.49,95%CI 1.10-5.64,P=0.03)。
  • 腺癌中TP53/EGFR共突变无预后(P=0.83)也无显著预测作用(P=0.86)。
  • 两组的无病生存结果相似。

局限性

  • TP53/KRAS共突变对化疗的潜在负向预测效应需验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Our previous work evaluated individual prognostic and predictive roles of TP53, KRAS, and EGFR in non-small-cell lung cancer (NSCLC). In this analysis, we explore the prognostic and predictive roles of TP53/KRAS and TP53/EGFR comutations in randomized trials of adjuvant chemotherapy versus observation. Patients and Methods Mutation analyses (wild-type [WT] and mutant) for TP53, KRAS, and EGFR were determined in blinded fashion in multiple laboratories. Primary and secondary end points of pooled analysis were overall survival and disease-free survival. We evaluated the role of TP53/KRAS comutation in all patients and in the adenocarcinoma subgroup as well as the TP53/EGFR comutation in adenocarcinoma only through a multivariable Cox proportional hazards model stratified by trial. Results Of 3,533 patients with NSCLC, 1,181 (557 deaths) and 404 (170 deaths) were used for TP53/KRAS and TP53/EGFR analyses. For TP53/KRAS mutation status, no prognostic effect was observed ( P = .61), whereas a borderline predictive effect ( P = .04) was observed with a deleterious effect of chemotherapy with TP53/KRAS comutations versus WT/WT (hazard ratio, 2.49 [95% CI, 1.10 to 5.64]; P = .03). TP53/EGFR comutation in adenocarcinoma was neither prognostic ( P = .83), nor significantly predictive ( P = .86). Similar results were observed for both groups for disease-free survival. Conclusion We could identify no prognostic effect of the KRAS or EGFR driver and TP53 tumor suppressor comutation. Our observation of a potential negative predictive effect of TP53/KRAS comutation requires validation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Shepherd FA, Lacas B, Le Teuff G, et al. Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. J Clin Oncol. 2017. PMID: 28453411. doi:10.1200/JCO.2016.71.2893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。